InvestorsHub on MSN
Vanda shares slide after FDA turns down jet lag use for HETLIOZ
Vanda Pharmaceuticals (NASDAQ:VNDA) saw its shares drop about 12% on Thursday after announcing that the U.S. Food and Drug Administration has declined to approve its application to use HETLIOZ for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback